貨號：GS40230

Enokizumab is an investigational, humanized monoclonal antibody developed for the treatment of moderate-to-severe plaque psoriasis and potentially other autoimmune diseases. It belongs to the class of targeted biologic therapies that inhibit specific pro-inflammatory cytokines. Enokizumab functions as a precision interleukin inhibitor, designed to bind and neutralize its target cytokine with high specificity in the extracellular space. By blocking the interaction between this cytokine and its receptor on immune and tissue cells, enokizumab aims to interrupt a key signaling pathway that drives the chronic inflammation, keratinocyte hyperproliferation, and abnormal skin cell differentiation characteristic of psoriasis.